---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-24-000214"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2024-11-01T23:59:59+00:00"
generated_at: "2026-05-30T07:11:12.714146+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Biosciences launches $300M accelerated share repurchase with Goldman Sachs

## Summary
- Entered into ASR agreement with Goldman Sachs & Co. to repurchase $300M of common stock.
- On Nov 4, 2024, will pay $300M and receive 80% of shares based on Oct 31 closing price.
- Final settlement expected in Q1 2025; additional shares or cash adjustments possible per terms.
- Repurchase conducted under previously announced $300M board-authorized share repurchase program.

## SEC filing metadata
- accession: 0000914475-24-000214
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2024-11-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447524000214/0000914475-24-000214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447524000214/nbix-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-24-000214
- JSON: https://secwatch.observer/filing/0000914475-24-000214.json
- Plain text: https://secwatch.observer/filing/0000914475-24-000214.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.